ALISO VIEJO, Calif., July 23, 2025 /PRNewswire/ — In a major milestone for chronic post-amputation pain treatment, the first commercial patient in the U.S. has been successfully implanted with the FDA-approved Altius® System – marking the beginning of the company’s mission to relieve pain and restore life for lower limb amputees.
The Altius System is the only FDA-approved on-label device designed specifically for the treatment of Chronic Post-Amputation Pain for lower limb amputees. The patient- initiated, on-demand direct electrical nerve stimulation blocks painful signals from reaching the brain, thus providing durable pain relief without the potential dependency of opioid medications. The Altius System expands treatment options for lower limb amputees who have failed conventional therapies.
“The first commercial implantation of the Altius System represents a significant advancement in the treatment of a large unmet medical need in chronic post-amputation pain and a critical step forward for expanding new indications for neuromodulation therapies,” said David Veino, President and CEO of Neuros Medical. “We are proud to offer new hope to patients who have limited options for durable pain relief.”
The implant procedure was performed at Baylor Scott & White Heart and Vascular Hospital in Dallas, TX, one of several leading institutions participating in the early commercial launch of the Altius System.
About the Altius® Direct Electrical Nerve Stimulation System
The Altius® System is a patient-controlled, on-demand system that uses Neuros’ patented technology to address the underlying cause of post-amputation pain by inhibiting pain signal transmission from the damaged peripheral nerves near the site of amputation to the central nervous system. The system consists of a nerve cuff electrode placed around an affected nerve and an implantable pulse generator (IPG). Patients initiate an on-demand 30-minute treatment session as needed for targeted pain relief. There are over two million patients in the United States with major limb amputations, and it is estimated up to 80% suffer from some form of chronic post-amputation pain.1, 2
The Altius System is FDA-approved and is indicated as an aid in the management of chronic intractable phantom and residual lower limb post-amputation pain in adult amputees. The Altius System is the only FDA-approved device that provides amputees with patient-controlled, on-demand relief by targeting the nerve pain directly.
Click here for important safety information.
About Neuros Medical, Inc.
There are over two million patients in the U.S. living with limb loss and approximately 300,000 new lower limb amputations occurring every year. Post-amputation pain includes both phantom limb pain and residual limb pain, and impacts up to 80% of amputees, representing a significant unmet medical need, as existing treatment options are limited and consist primarily of opioids and gabapentinoids. Neuros Medical is a privately held company and the maker of the Altius® Direct Electrical Nerve Stimulation System, which is FDA-approved and is indicated as an aid in the management of chronic intractable phantom and residual lower limb post-amputation pain in adult amputees. Our mission is to relieve pain and restore life for people suffering with post-amputation pain. We are a passionate team guided by our core values and committed to our patients and the healthcare professionals who care for them.
Our Core Values: Patients First, Deliver Excellence, Responsible Ambition, Inspire and Empower.
References
For additional information regarding Neuros Medical, please contact:
Steve Bosrock, Vice President, Marketing
sbosrock@neurosmedical.com
www.neurosmedical.com
Tel: 440-951-2565